WHO. Global Tuberculosis Report 2015. Geneva: World Health Organization, 2015.
Jaramillo, M. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. Geneva, Switzerland: World Health Organization [WHO], 2006.
MCR. The Global Plan to Stop TB, 2006–2015. International Journal of Tuberculosis & Lung Disease the Official Journal of the International Union against Tuberculosis & Lung Disease
2006; 10(2): 238–239.
WHO. Global tuberculosis control 2015. Global Tuberculosis Control
Lixia, W, et al.
Survey of the Fifth National epidemiological sampling of tuberculosis in 2010. Chinese Journal of Tuberculosis Prevention
2012; 34(08): 485–508.
World Health Organization. Stop TB Department Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization, 2006.
Qianghong, D, et al.
Treatment outcomes and risk factors for retreated smear positive pulmonary tuberculosis in Wuhan City. Chinese Journal of Tuberculosis Prevention
2013; 35(10): 788–792.
Yingjie, Y. Risk factors for the efficacy of retreated smear positive tuberculosis patients and nursing intervention. Jilin Medicine
2010; 31(34): 6350–6351.
Vicentin, G. Evoluçäo da mortalidade por tuberculose no município do Rio de Janeiro, 1979–1995. São Paulo, Brazil: Universidade de São Paulo, 2000.
Volmink, J, Garner, P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ (Clinical Research edn)
1997; 315(7120): 1403–1406.
Yaqin, L, Yuan, M, Wei, C. Risk factors for compliance of retreated tuberculosis patients. Nursing Research
2011; 25(29): 2649–2651.
Sullivan, LM, Massaro, JM, D'Agostino, RB. Sr
Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Statistics in Medicine
2004; 23(10): 1631–1660.
Shiming, C, et al.
Investigation and analysis on social factors of retreated smear positive pulmonary tuberculosis patients in Hunan Province. Practical Preventive Medicine
2003; 10(02): 132–134.
Kherosheva, T, et al.
Encouraging outcomes in the first year of a TB control demonstration program: Orel Oblast, Russia. The International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union against Tuberculosis and Lung Disease
2003; 7(11): 1045–1051.
Talay, F, Kumbetli, S, Altin, S. Factors associated with treatment success for tuberculosis patients: a single center's experience in Turkey. Japanese Journal of Infectious Diseases
2008; 61(1): 25–30.
D'Agostino, RB, et al.
Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke; a Journal of Cerebral Circulation
1994; 25(1): 40–43.
Yousefzadeh, G, et al.
Applying the Framingham risk score for prediction of metabolic syndrome: the Kerman Coronary Artery Disease Risk Study, Iran. ARYA Atherosclerosis
2015; 11(3): 179–185.
Goldstein LB, BC, Adams, RJ, Appel, LJ, Braun, LT, Chaturvedi, S, Creager, MA, Culebras, A, Eckel, RH, Hart, RG, Hinchey, JA, Howard, VJ, Jauch, EC, Levine, SR, Meschia, JF, Moore, WS, Nixon, JV, Pearson, TA; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke
2011; 42(2): 517–584.
Wang, H, et al.
Longitudinal association of dairy consumption with the changes in blood pressure and the risk of incident hypertension: the Framingham Heart Study. The British journal of nutrition
2015; 114(11): 1887–1899.
Jacob, ST, Pavlinac, PB, Nakiyingi, L, Banura, P, Baeten, JM, Morgan, K, et al.
Mycobacterium tuberculosis Bacteremia in a Cohort of HIV-infected patients hospitalized with severe sepsis in Uganda–high frequency, low clinical sand derivation of a Clinical Prediction Score. PLoS ONE
2013; 8(8): e70305.
Joshi, PH, et al.
Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association
Parikh, NI, et al.
A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Annals of Internal Medicine
2008; 148(2): 102–110.
Chen, S, et al.
Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case–control study. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases
2013; 17(12): e1116–1120.
Lenjisa, J. Assessment of tuberculosis retreatment case rate and its treatment outcomes at Adama Hospital Medical College, East Showa, Ethiopia. Journal of Steroids & Hormonal Science
Jones-Lopez, EC, et al.
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Medicine
2011; 8(3): e1000427.
Mpagama, SG, et al.
The influence of mining and human immunodeficiency virus infection among patients admitted for retreatment of tuberculosis in Northern Tanzania. The American Journal of Tropical Medicine and Hygiene
2015; 93(2): 212–215.
Kritski, AL, et al.
Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest
1997; 111(5): 1162–1167.
Espinal, MA, et al.
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Jama
2000; 283(19): 2537–2545.
He, GX, et al.
Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS ONE
2010; 5(5): e10799.
Green, E, et al.
Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen. Journal of Health, Population, and Nutrition
2010; 28(1): 7–13.
Mak, A, et al.
Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. American Journal of Respiratory and Critical care Medicine
2008; 178(3): 306–312.
Faustini, A, Hall, AJ, Perucci, CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax
2006; 61(2): 158–163.
Choi, H, et al.
Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005–2012. BMC Infectious Diseases
2014; 14(1): 360.
Jian, D, et al.
Reasons for failure of Standardized short term chemotherapy regimen for initial or retreated pulmonary tuberculosis patients. Chinese Journal of Parasitic Disease
2012; 7(07): 523–526.
Yang, Z, et al.
Risk factors for sputum culture result at the end of 2nd month of treatment in MDR-TB patients. Chinese Journal of Tuberculosis Prevention
2015; 37(1): 74–79.